Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B‐cell lymphoma and suggests patients’ survival benefit from rituximab
- 18 November 2008
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 81 (6), 448-453
- https://doi.org/10.1111/j.1600-0609.2008.01129.x
Abstract
To evaluate the prognostic value of absolute lymphocyte count (ALC) at diagnosis in patients with diffuse large B-cell lymphoma (DLBCL). In a large cohort of patients with DLBCL treated with CHOP (n = 119) or RCHOP (n = 102) in our institution, we evaluated the prognostic value of ALC at diagnosis with regards to treatment response, overall (OS) and progression-free survival (PFS). Use of rituximab, all International Prognostic Index (IPI) determinants, beta2microglobulin level, presence of B symptoms or bulky disease, and ALC were evaluated. Low ALC (or=2, elevated lactate dehydrogenase, number of extranodal involvement >or=2, B symptoms, elevated beta2microglobulin and higher IPI risk group. Low ALC was associated with lower CR rate by univariate analysis (odds ratio = 3.29, P = 0.024) but not by multivariate analysis. By univariate analysis using Cox proportional hazard model, low ALC was associated with shorter OS [hazard ratio (HR) = 2.89, P < 0.001] and PFS (HR = 2.91, P < 0.001). Multivariate analysis revealed that low ALC was associated with shorter OS (HR = 2.51, P = 0.003) and PFS (HR = 2.72, P < 0.001), independent of above-mentioned parameters. Subclass analyses revealed that the use of rituximab improves OS in patients with low ALC (HR = 0.42, P = 0.05) but not in those with high ALC (HR = 0.83, P = 0.71). This observation was most obvious in patients with higher IPI score. Low ALC is a poor prognostic marker in patients with DLBCL and suggests patients' survival benefit from rituximab.Keywords
This publication has 11 references indexed in Scilit:
- Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphomaBritish Journal of Haematology, 2008
- Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomasLeukemia & Lymphoma, 2008
- Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphomaLeukemia, 2007
- Absolute lymphocyte count predicts overall survival in follicular lymphomasBritish Journal of Haematology, 2006
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958